Literature DB >> 3335604

Side-effects of spironolactone therapy in the hirsute woman.

E L Helfer1, J L Miller, L I Rose.   

Abstract

Spironolactone, an aldosterone antagonist with antiandrogenic activities, is often used to treat hirsute women. Several investigators have reported beneficial effects of such treatment, but the dosages used and side-effects encountered differ in their reports. To clarify this issue, 26 consecutive premenopausal women with idiopathic hirsutism were prospectively evaluated during spironolactone treatment. Sixteen women initially received 100 mg spironolactone twice daily on days 4-21 of their menstrual cycles. In 11 women (68%), the dosage had to be decreased or the medication discontinued due to side-effects. The major side-effect, metrorrhagia with 14-day cycles, occurred in 9 women (56%). This side-effect, while not dangerous, was intolerable to these women. In one woman, spironolactone was discontinued because of urticaria and in another because of scalp hair loss. Ten women initially received 50 mg spironolactone twice daily on days 4-21 of their menstrual cycles. Two developed metrorrhagia, but no other side-effects were noted. Because of the incidence of metrorrhagia at higher dosages, we recommend that spironolactone be administered cyclically at a starting dosage of 50 mg twice daily on days 4-21 of the menstrual cycle. Alternatively, one may consider adding cyclical estrogen/progesterone therapy to continuous spironolactone therapy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3335604     DOI: 10.1210/jcem-66-1-208

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

Review 1.  Aldosterone as a determinant of cardiovascular and renal dysfunction.

Authors:  M Epstein
Journal:  J R Soc Med       Date:  2001-08       Impact factor: 5.344

Review 2.  Hirsutism: evaluation and management.

Authors:  R E Watson; R Bouknight; P C Alguire
Journal:  J Gen Intern Med       Date:  1995-05       Impact factor: 5.128

Review 3.  A risk-benefit assessment of pharmacological therapies for hirsutism.

Authors:  E Carmina
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 4.  Aldosterone receptor antagonists: biology and novel therapeutical applications.

Authors:  P Magni; M Motta
Journal:  J Endocrinol Invest       Date:  2003-08       Impact factor: 4.256

5.  Effect of finasteride in idiopathic hirsutism.

Authors:  E Faloia; S Filipponi; V Mancini; S Di Marco; F Mantero
Journal:  J Endocrinol Invest       Date:  1998-11       Impact factor: 4.256

6.  Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI.

Authors:  C Sabbadin; A Andrisani; M Zermiani; G Donà; L Bordin; E Ragazzi; M Boscaro; G Ambrosini; D Armanini
Journal:  J Endocrinol Invest       Date:  2016-04-12       Impact factor: 4.256

Review 7.  Management of hirsutism.

Authors:  N K Agrawal
Journal:  Indian J Endocrinol Metab       Date:  2013-10

Review 8.  The Menstrual Disturbances in Endocrine Disorders: A Narrative Review.

Authors:  Marzieh Saei Ghare Naz; Marzieh Rostami Dovom; Fahimeh Ramezani Tehrani
Journal:  Int J Endocrinol Metab       Date:  2020-10-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.